-
公开(公告)号：EP1838680A2
公开(公告)日：2007-10-03
申请号：EP06706226.5
申请日：2006-01-13
申请人： Novartis AG , NOVARTIS-PHARMA GMBH
IPC分类号： C07D245/06 , C07D281/00 , A61P25/28 , A61K31/395
CPC分类号： C07D273/02 , C07D245/06 , C07D291/08 , C07D413/04 , C07D413/12 , C07D419/12
摘要： The invention relates to novel macrocyclic compounds of the formula in which R1, R3, V1, V2, X1, X2, Y, Z, Ar, AA and n are as defined in the specification, the number of ring atoms included in the macrocyclic ring being 14, 15, 16, 17 or 18, in free base form or in acid addition salt form, to their preparation, to their use as medicaments and to medicaments comprising them.
-
公开(公告)号：EP1851208A1
公开(公告)日：2007-11-07
申请号：EP06701373.0
申请日：2006-01-13
申请人： Novartis AG , Novartis Pharma GmbH
发明人： BETSCHART, Claudia , LERCHNER, Andreas , MACHAUER, Rainer , RÜEGER, Heinrich , TINTELNOT-BLOMLEY, Marina , VEENSTRA, Siem, Jacob
IPC分类号： C07D273/02
CPC分类号： C07D273/00 , C07D245/04 , C07D273/02 , C07D413/04 , C07D413/12 , C07D413/14 , C07D471/08
摘要： The invention relates to novel macrocyclic compounds of the formula (I), in which all of the variables are as defined in the specification, the number of ring atoms included in the macrocyclic ring being 14, 15, 16 or 17, in free base form or in acid addition salt form, to their preparation, to their use as medicaments and to medicaments comprising them.
-
公开(公告)号：EP3199158B1
公开(公告)日：2019-04-17
申请号：EP17157570.7
申请日：2013-11-11
申请人： Novartis AG
发明人： FAIRHURST, Robin Alec , FURET, Pascal , KALTHOFF, Frank Stephan , LERCHNER, Andreas , RUEEGER, Heinrich
IPC分类号： A61K31/506 , A61P17/00
-
公开(公告)号：EP2922848B1
公开(公告)日：2017-06-28
申请号：EP13795867.4
申请日：2013-11-11
申请人： Novartis AG
发明人： FAIRHURST, Robin, Alec , FURET, Pascal , KALTHOFF, Frank, Stephan, Dr. , LERCHNER, Andreas , RUEEGER, Heinrich
IPC分类号： C07D413/14 , C07D417/14 , A61K31/506 , A61P35/00
CPC分类号： C07D417/14 , A61K31/5377 , A61K45/06 , C07D413/14
-
公开(公告)号：EP2922848A1
公开(公告)日：2015-09-30
申请号：EP13795867.4
申请日：2013-11-11
申请人： Novartis AG
发明人： FAIRHURST, Robin Alec , FURET, Pascal , KALTHOFF, Frank Stephan , LERCHNER, Andreas , RUEEGER, Heinrich
IPC分类号： C07D413/14 , C07D417/14 , A61K31/506 , A61P35/00
CPC分类号： C07D417/14 , A61K31/5377 , A61K45/06 , C07D413/14
摘要： The present invention relates to oxazolidin-2-one substituted pyrimidine compounds that act as PI3K (phosphatidylinositol-3-kinase) inhibitors, as well as pharmaceutical compositions thereof, methods for their manufacture and uses for the treatment of conditions, diseases and disorders dependent on PI3K.
摘要翻译： 本发明涉及作为PI3K（磷脂酰肌醇-3-激酶）抑制剂的恶唑烷-2-酮取代的嘧啶化合物及其药物组合物，其制备方法和用于治疗依赖于 PI3K。
-
公开(公告)号：EP1968954A1
公开(公告)日：2008-09-17
申请号：EP06841191.7
申请日：2006-12-28
申请人： Novartis AG
发明人： BETSCHART, Claudia , KOLLER, Manuel , LAUMEN, Kurt , LERCHNER, Andreas , MACHAUER, Rainer , MCCARTHY, Clive , TINTELNOT-BLOMLEY, Marina , VEENSTRA, Siem, Jacob
IPC分类号： C07D245/04 , A61P25/00 , A61K31/33
CPC分类号： C07D245/04 , C07D273/00
摘要： The invention relates to novel macrocyclic compounds of the formula (I), in which all of the variables are as defined in the specification, in free base form or in acid addition salt form, to their preparation, to their use as medicaments and to medicaments comprising them.
-
公开(公告)号：EP2771342B1
公开(公告)日：2016-05-18
申请号：EP12798854.1
申请日：2012-10-26
申请人： Novartis AG
发明人： BRIARD, Emmanuelle , FURET, Pascal , LERCHNER, Andreas , MEIER, Peter , RADETICH, Branko , SANDHAM, David Andrew , ZHU, Yanyi
IPC分类号： C07D473/16 , C07D519/00
CPC分类号： C07D473/16 , A61K31/5377 , A61K31/553 , C07D487/04 , C07D491/048 , C07D491/107 , C07D519/00
-
公开(公告)号：EP2771342A1
公开(公告)日：2014-09-03
申请号：EP12798854.1
申请日：2012-10-26
申请人： Novartis AG
发明人： BRIARD, Emmanuelle , FURET, Pascal , LERCHNER, Andreas , MEIER, Peter , RADETICH, Branko , SANDHAM, David Andrew , ZHU, Yanyi
IPC分类号： C07D473/16 , C07D519/00
CPC分类号： C07D473/16 , A61K31/5377 , A61K31/553 , C07D487/04 , C07D491/048 , C07D491/107 , C07D519/00
摘要： The invention relates to PI3K inhibitors of the formula (I) • in which all of the variables are as defined in the specification, to their preparation, to their medical use, in particular to their use in the treatment of cancer and neurodegenerative disorders, and to medicaments comprising them.
-
9.发明公开OXAZOLIDIN-2-ONE-PYRIMIDINE DERIVATIVES FOR USE IN THE TREATMENT OF SKIN FIBROSIS, SCLERODERMA, HYPERTROPHIC SCARS OR KELOIDS 审中-公开恶唑啉-2-酮 - 嘧啶衍生物用于治疗皮肤纤维化，鳞屑病，肥厚性瘢痕或皮肤瘙痒症
公开(公告)号：EP3199158A1
公开(公告)日：2017-08-02
申请号：EP17157570.7
申请日：2013-11-11
申请人： Novartis AG
发明人： FAIRHURST, Robin Alec , FURET, Pascal , KALTHOFF, Frank Stephan , LERCHNER, Andreas , RUEEGER, Heinrich
IPC分类号： A61K31/506 , A61P17/00
CPC分类号： C07D417/14 , A61K31/5377 , A61K45/06 , C07D413/14
摘要： The present invention relates to oxazolidin-2-one substituted pyrimidine compounds that act as PI3K (phosphatidylinositol-3-kinase) inhibitors, as well as pharmaceutical compositions thereof, methods for their manufacture and uses for the treatment of conditions, diseases and disorders dependent on PI3K.
摘要翻译： 本发明涉及充当PI3K（磷脂酰肌醇-3-激酶）抑制剂的恶唑烷-2-酮取代的嘧啶化合物及其药物组合物，其制备方法和用于治疗依赖于下列疾病的疾病和病症的用途： PI3K。
-
10.发明公开2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL-SULFONAMIDE DERIVATIVES 审中-公开2,4-二氧代-1,4-二氢-2H-CHINAZOLIN -3- YL-SULFONAMIDDERIVATE
公开(公告)号：EP2571865A1
公开(公告)日：2013-03-27
申请号：EP11719840.8
申请日：2011-05-18
申请人： Novartis AG
IPC分类号： C07D403/04 , C07D405/04 , A61P25/08 , A61K31/517
CPC分类号： C07D403/04 , C07D239/96 , C07D405/04
摘要： The invention relates to a 2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl-sulfonamide derivative being (A) a compound of the formula (I) in which the substituents are as defined in the specification; in free form or in salt form; or (B) a compound selected from a certain group of 2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl-sulfonamide derivatives disclosed in the specification; in free form or in salt form; to their preparation, to their use as medicament and to medicaments comprising them. In a first aspect, the invention provides prodrugs of AMPA receptor antagonists which potentially useful in the treatment of a wide range of disorders, particularly epilepsy.
-
-
-
-
-
-
-
-
-
搜索结果
10 条记录 (耗时 0.019 秒)
